JATT vs. ATOS, ALTS, CLYM, ACOG, RANI, CRBP, ARTV, ELUT, ZURA, and VOR
Should you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include Atossa Therapeutics (ATOS), Janone (ALTS), Climb Bio (CLYM), Alpha Cognition (ACOG), Rani Therapeutics (RANI), Corbus Pharmaceuticals (CRBP), Artiva Biotherapeutics (ARTV), Elutia (ELUT), Zura Bio (ZURA), and Vor Biopharma (VOR). These companies are all part of the "pharmaceutical products" industry.
JATT Acquisition vs.
Atossa Therapeutics (NASDAQ:ATOS) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.
Atossa Therapeutics received 240 more outperform votes than JATT Acquisition when rated by MarketBeat users.
Atossa Therapeutics currently has a consensus target price of $7.00, indicating a potential upside of 780.28%. Given Atossa Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Atossa Therapeutics is more favorable than JATT Acquisition.
Atossa Therapeutics' return on equity of -35.74% beat JATT Acquisition's return on equity.
In the previous week, Atossa Therapeutics had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 1 mentions for Atossa Therapeutics and 0 mentions for JATT Acquisition. Atossa Therapeutics' average media sentiment score of 1.94 beat JATT Acquisition's score of 0.00 indicating that Atossa Therapeutics is being referred to more favorably in the media.
12.7% of Atossa Therapeutics shares are held by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are held by institutional investors. 7.6% of Atossa Therapeutics shares are held by insiders. Comparatively, 20.0% of JATT Acquisition shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Atossa Therapeutics beats JATT Acquisition on 7 of the 11 factors compared between the two stocks.
Get JATT Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for JATT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
JATT Acquisition Competitors List
Related Companies and Tools
This page (NYSE:JATT) was last updated on 2/22/2025 by MarketBeat.com Staff
